James Yang

National Cancer Institute
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (7)

Year:

2025

In a first for solid cancers, cellular immunotherapy has entered standard of care in the treatment of patients with metastatic melanoma. The infusion of autologous tumor-infiltrating T lymphocytes (TIL) is capable of mediating durable tumor regression and is now Food and Drug Administration-approved for patients with disease refractory to immune checkpoint inhibitors. Since the advent of chimeric antigen receptor (CAR) T cells for patients with hematological malignancies, a growing network of centers capable of delivering effector T cell products to patients has developed. Administration of TIL can be layered onto that institutional framework, but there are many complex and unique aspects to TIL immunotherapy. The highly multidisciplinary clinical expertise and coordination required to successfully and safely deliver TIL to patients began within the National Cancer Institute Surgery Branch and have been subsequently adopted worldwide. The general steps, most of which require hospital inpatient resources, include a surgical procedure to harvest sufficient tumor for TIL manufacturing, admission for non-myeloablative lymphodepleting chemotherapy followed by TIL, and intravenous interleukin-2 (IL-2, aldesleukin). Here, we provide the principles, practice, and required resources underlying the efficient and safe delivery of TIL immunotherapy derived from the clinical expertise of high-volume centers around the world. This article enhances published clinical practice guidelines by providing underlying clinical rationale and data-driven examples to demystify TIL immunotherapy in order to facilitate uptake and improve patient access to this promising treatment modality in clinical and research settings.

Year:

2025

Extent of IMPACT CpG island promoter methylation in mouse cell lines (KPC, 4964-POP, and 4964-HOP), and five human pancreatic liver metastases compared to three primary PDACs, and two normal pancreas and liver tissue.

Year:

2025

List of all hits identified in the cDNA screen and categorized by function. cDNAs highlighted in red were identified in the 3 KB library fraction. The number of tumor lesions identifying the cDNA is given.

Year:

2025

Given the propensity of aggressive epithelial tumors to form hepatic metastases, we performed an in vivo cDNA screen using the mouse liver and KRAS G12D / TP53 R273H pancreatic cells that identified the RNA-binding protein GCN1 as an integral component of hepatic outgrowth. RNAi experiments reveal that GCN1 triggers the integrated stress response (ISR) to activate serine, folate, and methionine biosynthetic pathways together with amino acid transporters, which act in concert to facilitate acquisition of metabolites and to restore redox homeostasis. Alongside the activation of the ISR, we found that GCN1 also functions in the nucleus where it interacts with HNRNPK to suppress the expression of MHC-I molecules and NK ligands. Intriguingly, we identified IMPACT as an endogenous competitive inhibitor of GCN1 that blocks both ISR-dependent metabolic control and disrupts HNRNPK interaction. In doing so, IMPACT enhances tumor immunogenicity to unleash NK cell killing, in addition to sensitizing metastatic tumor cells to immune checkpoint blockade. Significance: Metastatic tumor cells display profound immunometabolic plasticity to colonize distant organs. We identify IMPACT, an inhibitor of GCN1-stress signaling, expression of which curtailed metabolic plasticity and augmented tumor immunogenicity, sensitizing metastatic tumor cells to NK cell–mediated destruction.

Year:

2025

Adoptive cell transfer (ACT) using neoantigen reactive T lymphocytes can mediate cancer regression. Here, we developed methods to isolate unique, personalized, neoantigen reactive T cell receptors (TCRs) from tumor infiltrating lymphocytes (TIL) from patients with metastatic gastrointestinal cancers and incorporate the TCR α and β chains into gamma retroviral vectors. We transduced autologous peripheral blood lymphocytes (PBL) using γ-retroviruses and adoptively transferred those cells into patients after lymphodepleting chemotherapy. We treated 7 patients with metastatic, mismatch-repair proficient colorectal cancers who had progressive disease following multiple prior therapies, and three patients had objective clinical responses by RECIST criteria including regressions of metastases to the liver, lung, and lymph nodes. All patients received T cell populations containing ≥50% TCR transduced cells, and all T cell populations were polyfunctional in that they secreted IFNα, GM-CSF, IL-2, and Granzyme B specifically in response to mutant peptides compared to wild type counterparts. TCR transduced cells were detected in the peripheral blood of 5 patients, including the three responders, at levels ≥10% of CD3+ cells approximately one month post-ACT. In one patient with a partial response to therapy, ~20% of CD3+ PBL expressed transduced TCRs more than two years after treatment. These studies demonstrate that ACT with T cells genetically modified to express personalized neoantigen reactive TCRs is safe and can mediate tumor regression in patients with metastatic solid epithelial cancers.

Year:

2024

Mutations in KRAS are some of the most common across multiple cancer types and are thus attractive targets for therapy. Recent studies demonstrated that mutant KRAS generates immunogenic neoantigens that can be targeted in adoptive T cell therapy in metastatic diseases. To expand mutant KRAS specific immunotherapies, it is critical to identify additional HLA-I allotypes that can present KRAS neoantigens and their cognate T cell receptors (TCR). Here, we identified a murine TCR specific to a KRAS-G12V neoantigen ( 7 VVVGAVGVGK 16 ) using a vaccination approach with transgenic mice expressing the common HLA-I allotype, HLA-A*03:01 (HLA-A3). This TCR demonstrated exquisite specificity for mutant G12V and not Wt KRAS peptides. To investigate the molecular basis for neoantigen recognition by This TCR, we determined its structure in complex with HLA-A3(G12V). G12V-TCR CDR3β and CDR1 β formed a hydrophobic pocket to interact with p6 Val of the G12V but not Wt KRAS peptide. To improve the tumor sensitivity of This TCR, we designed rational substitutions to improve TCR:HLA-A3 contacts. Two substitutions exhibited modest improvements in TCR binding to HLA-A3 (G12V), but did not sufficiently improve T cell sensitivity for further clinical development. Our study provides mechanistic insight into how TCRs detect neoantigens and reveals the challenges in targeting KRAS-G12V mutations. [203]

Year:

2024

Collaborators (15)

Todd Prickett

Staff Scientist

National Institutes of Health

UNITED STATES
View details

Pankaj Singh

Professor and Chair

University of Oklahoma Health Sciences Center

UNITED STATES
View details

Kirsten Remmert

Staff Scientist

National Institutes of Health

UNITED STATES
View details

Marina Pasca Di Magliano

Associate Professor

University of Michigan

UNITED STATES
View details

Alexander Rossi

Assistant Professor

Yale University

UNITED STATES
View details

Margaret Cam

Staff Scientist

National Institutes of Health

UNITED STATES
View details

Rodrigo Xavier das Neves

Research Assistant Professor

University of Pittsburgh

UNITED STATES
View details

Carolina Larrain

NYU Langone Health

UNITED STATES
View details

Reed Ayabe

Assistant Professor

University of California Irvine Medical Center

UNITED STATES
View details

Jeremy Davis

Professor and Chief, Division of Surgical Oncology

University of Maryland School of Medicine

UNITED STATES
View details

Malcolm Sim

University of Oxford

UNITED KINGDOM
View details

Sri Krishna

Stadtman Investigator

National Cancer Institute

UNITED STATES
View details

Costas A. Lyssiotis

University of Michigan

UNITED STATES
View details

Jared Gartner

National Institutes of Health

UNITED STATES
View details

sivasish sindiri

National Cancer Institute

UNITED STATES
View details